Oncor status In a phase I clinical trial, ONCOS-102 was found to be safe and well-tolerated in patients with advanced solid tumors. The most common adverse events were mild to moderate flu-like symptoms, which resolved on their own within a few days. Importantly, ONCOS-102 showed signs of clinical activity, with some patients experiencing tumor shrinkage or stable disease. Based on these promising results, Transgene SA has initiated several phase II clinical trials to further evaluate the safety and efficacy of ONCOS-102 in various types of cancer, including mesothelioma, ovarian cancer, and liver cancer. These trials are designed to assess the potential benefits of combining ONCOS-102 with other cancer treatments, such as checkpoint inhibitors and chemotherapy. One of the key advantages of ONCOS-102 is its ability to stimulate a systemic immune response against cancer cells. This means that it can potentially target cancer cells throughout the body, even those that are not directly infected by the virus. This is in contrast to other oncolytic viruses, which are typically only able to kill cancer cells in the immediate vicinity of the infection. In a phase I clinical trial, ONCOS-102 was found to be safe and well-tolerated in patients with advanced solid tumors. The most common adverse events were mild to moderate flu-like symptoms, which resolved on their own within a few days. Importantly, ONCOS-102 showed signs of clinical activity, with some patients experiencing tumor shrinkage or stable disease. Based on these promising results, Transgene SA has initiated several phase II clinical trials to further evaluate the safety and efficacy of ONCOS-102 in various types of cancer, including mesothelioma, ovarian cancer, and liver cancer. These trials are designed to assess the potential benefits of combining ONCOS-102 with other cancer treatments, such as checkpoint inhibitors and chemotherapy. One of the key advantages of ONCOS-102 is its ability to stimulate a systemic immune response against cancer cells. This means that it can potentially target cancer cells throughout the body, even those that are not directly infected by the virus. This is in contrast to other oncolytic viruses, which are typically only able to kill cancer cells in the immediate vicinity of the infection. Another advantage of ONCOS-102 is its potential to overcome resistance to checkpoint inhibitors, which are a type of immunotherapy drug that has shown promising results in some types of cancer. Checkpoint inhibitors work by blocking the ability of cancer cells to evade the immune system, but they are not effective in all patients. ONCOS-102 has been shown to increase the expression of PD-L1, a protein that is targeted by checkpoint inhibitors, on cancer cells, which may enhance the effectiveness of these drugs. In summary, ONCOS-102 is a novel immunotherapy drug that has shown promising results in early-stage clinical trials. Its dual mechanism of action, which combines oncolysis and immunotherapy, makes it a promising new approach to cancer treatment. Several phase II clinical trials are currently underway to further evaluate the safety and efficacy of ONCOS-102 in various types of cancer.
In conclusion, HR.Emory.edu is a valuable resource for current and prospective Emory employees. The site provides comprehensive information about employment opportunities, benefits, policies, and training programs, and is designed to be user-friendly and accessible. With its commitment to diversity, inclusion, data privacy, and security, HR.Emory.edu is an essential tool for anyone interested in working at Emory University.